Images List Premium Download Classic

Obesity

Obesity-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Growth differentiation factor 15 (gdf-15) polypeptides
Amgen Inc.
October 12, 2017 - N°20170291929

Gdf15 polypeptides, constructs comprising gdf15, and mutants thereof are provided. In various embodiments the gdf15 polypeptides, constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Adeno-associated viral vectors for the gene therapy of metabolic diseases
Universitat Autonoma De Barcelona
October 12, 2017 - N°20170290926

The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors. The invention also relates to pharmaceutical compositions comprising said vectors.
Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
Endorecherche, Inc.
October 12, 2017 - N°20170290847

Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low dhea or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (dhea) and a selective estrogen receptor ...
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of dihydrocholesterol
Nestec S.a.
October 05, 2017 - N°20170281650

The use of dihydrocholesterol (dhc) in low doses of up to 50 mg per kg of body weight to treat or prevention excess weight or obesity and/or hyperlipidemia, and/or a disorders associated with any of the foregoing, and a composition comprising dhc.
Vegfc production promoter
Shiseido Company, Ltd.
October 05, 2017 - N°20170281500

The purpose of this invention is to find a novel fragrance component effective for prevention or control of swelling, lymphedema, skin aging or obesity from the viewpoint of activation of lymph vessel function by promotion of the expression of vegfc. This invention provides a swelling improving agent, lymph vessel activator and vegfc production promoter characterized by containing one or a ...
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (...
Amgen Inc.
September 28, 2017 - N°20170275370

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the gipr polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a glp-1 receptor agonist.
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
The Regents Of The University Of California
September 28, 2017 - N°20170275249

Compositions and methods are disclosed that relate to small molecule lipopeptidomimetic inhibitors of mammalian ghrelin o-acyl transferase (goat). Compounds of general formula (i) and substructures thereof, i. E., formulae (ii), (iia), (iia1), (iia2), (iib), (iib1), (iib2), (iic) and (iii), are shown to exhibit potent inhibition of the octanoylation of ghrelin peptide, where the resulting non-octanoylated (des-acyl) form of ghrelin lacks ...
Prebiotics for reducing the risk of obesity later in life
Nestec S.a.
September 28, 2017 - N°20170273997

The invention proposes a nutritional composition comprising selected oligosaccharides that reduces the abundance of streptococcus bacteria in the gut of infants or young mammals. The infants are preferably infants in needs presenting a relatively high count of streptococcus. Ultimately the reduction of streptococcus and the related microbiota balance affects and lowers the risk of adiposity or obesity later in life.
Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170273966

The present invention relates to a compound represented by formula i:and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2. The compounds of the present invention may be useful in the treatment of hepatic ...
Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170273965

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula (i) are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2. The compounds of the present invention may be useful in the treatment of hepatic ...
Methods, devices, and systems for obesity treatment
Fulfillium, Inc.
September 28, 2017 - N°20170273813

In one aspect, a gastric balloon structure includes multiple isolated non-concentric inflatable chambers and a valve system for introducing fluid into each chamber, where the structure assumes, upon inflating, a curved shape conforming to a natural three-dimensional kidney shape of the gastric cavity.
Compositions and methods for diagnosis and treatment of metabolic syndrome
United States Of America, As Represented By The Secretary Of The Navy
September 21, 2017 - N°20170266144

Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
Intragastric device for treating obesity
Synerz Medical, Inc.
September 21, 2017 - N°20170266027

An intragastric device including (1) a first wire mesh structure having a pre-deployment shape, a post-deployment shape greater than the pre-deployment state, and one or more openings on an upper portion of the first wire mesh structure that are configured to permit food to enter the device, (2) a second wire mesh structure having a pre-deployment shape a post-deployment shape greater than ...
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of ...
Shire International Gmbh
September 14, 2017 - N°20170260185

The present invention provides compounds of formula (i) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4. 5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (dat) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, tourette syndrome, angelman syndrome, attention deficit disorder (add), attention deficit hyperactivity disorder (adhd), obesity, pain, obsessive-compulsive disorder, movement ...
Fgf-8 for use in treating diseases or disorders of energy homeostasis
Technische Universität München
September 14, 2017 - N°20170258874

The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis. Also provided by the present invention are pharmaceutical compositions comprising said polypeptides and ...
Anti-obesity composition
Technische Universität München
September 14, 2017 - N°20170258822

(b) at least one member selected from the group consisting of sulforaphane compounds and willow extract.
Non-inflatable gastric implants and systems
Apollo Endosurgery Us, Inc.
September 14, 2017 - N°20170258617

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, ...
2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof
Fudan University
September 07, 2017 - N°20170253564

2-alkoxy benzene formyl arylamine compounds and their pharmaceutical salts are disclosed. The compounds can act as sphingomyelin synthase (sms) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin (sm). The pharmaceutically acceptable salts and pharmaceutical compositions of the compounds are used as active ingredients in drugs which can prevent and cure diseases caused by sm level abnormal increase. These ...
Compounds against ralstonia pickettii for use in the treatment of insulin resistance, and method of ...
Wageningen Universiteit
September 07, 2017 - N°20170252421

Compounds disclosed herein are effective against ralstonia pickettii for treating or preventing insulin resistance, obesity or type ii diabetes of a subject, and include an antibiotic effective against ralstonia pickettii, an immunogenic compound producing a protective immune response, or an antibody which specifically binds to ralstonia pickettii or a fragment thereof. In vitro methods for diagnosis or prediction of insulin ...
Probiotic bifidobacterium adolescentis strains
Chr. Hansen A/s
September 07, 2017 - N°20170252382

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated ...
Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases
Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine
September 07, 2017 - N°20170252381

Provided are uses of bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity-related diseases. Also provided are a pharmaceutical composition, a medicament, a food product, and an animal feed that comprise bacteroides, uses thereof in treatment or prevention of obesity-related diseases, and a method for treatment or prevention of obesity-related diseases.
Loading